Argenx announces european commission approval of subcutaneous vyvgart® (efgartigimod alfa) for generalized myasthenia gravis

Vyvgart® is now approved for both intravenous (iv) and self-administered subcutaneous (sc) use in europe argenx is committed to continued collaboration with local authorities across the region to enable broad access to vyvgart sc for eligible patients amsterdam, the netherlands— november 16, 2023 —argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the european commission (ec) approved sc injectable vyvgart (efgartigimod alfa) as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) antibody positive. the ec previously approved vyvgart iv in august 2022.
ARGX Ratings Summary
ARGX Quant Ranking